solution à diluer pour perfusion clinical trials
19 indexed studies · 0 currently recruiting
- AuthorisedTherapeutic exploratory (Phase II)
Safety and Efficacy of Neoadjuvant immunotherapy with Durvalumab (MEDI 4736) in combination with neoadjuvant chemotherapy (Gemcitabin/Cisplatin or Gemcitabin/Carboplatin) in patients with operable, high-risk, localized urothelial carcinoma of the upper urinary tract. iNDUCT - GETUG V08
This study is looking at a new combination of treatments for a type of bladder or kidney cancer which has not spread. It combines a new drug (Durvalumab) with standard chemotherapy to see if it can shrink the cancer before surgery, aiming to remove all cancer cells.
For: The patient has a histologically-confirmed (ureteroscopic biopsy) or cytologically(urine cytology)-confirmed diagnosis of high-grade urothelial carcinoma of the renal pelvis or ureter.France - AuthorisedTherapeutic confirmatory (Phase III)
LEONARD.LEvOsimendaN vs. Placebo Before Tricuspid VAlve Surgery in Patients with Right Ventricular Dysfunction (LEONARD)
This study is looking at whether a drug called levosimendan can help patients undergoing heart surgery for a leaky heart valve. It aims to see if this medicine can reduce serious problems like low heart output in the first 90 days after surgery.
For: Patients referred for an isolated or a combined surgical correction of functional moderate to severe tricuspid regurgitationFrance - Ongoing, recruitingTherapeutic exploratory (Phase II)
A phase II randomized trial, non comparative, evaluating chemotherapy associated cisplatin, 5-fluorouracil and docetaxel at adapted doses in patients with locally advanced squamous cell carcinoma
This study looks at different chemotherapy drugs for people with a certain type of head and neck cancer that hasn't spread far. It checks how well a combination of treatments works after 8 weeks and if it helps people live longer and have a better quality of life.
For: locally advanced squamous cell carcinomaFrance - AuthorisedTherapeutic exploratory (Phase II)
Phase II study to evaluate the efficacy of 12-month neoadjuvant chemotherapy in terms of disease-free survival in patients with localized digestive neuroendocrine carcinomas - NEONEC D19-01
This study is looking at how well a combination of chemotherapy medicines works before surgery for a specific type of cancer called neuroendocrine carcinoma. It aims to see if this treatment helps people stay cancer-free for longer.
For: Localized digestive Neuroendocrine CarcinomasFrance - Ongoing, recruitingTherapeutic exploratory (Phase II)
TARSARC : TARGETING ATR IN SOFT-TISSUE SARCOMAS: A RANDOMIZED PHASE II STUDY
This study looks at a new drug, berzosertib, combined with standard gemcitabine chemotherapy, for adults with a type of soft-tissue cancer called leiomyosarcoma. It aims to see if the combination can better control the cancer's growth or shrink it, compared to gemcitabine alone.
For: Adult patients with locally advanced/unresectable and/or metastatic soft-tissue leiomyosarcomas.France - Ongoing, recruitingTherapeutic exploratory (Phase II)
OPTIMUNE-LUNG : INTEGRATIVE ANALYSIS OF THE TUMOR MICROENVIRONMENT AND OPTIMIZATION OF THE IMMUNOTHERAPY DURATION IN NON-SMALL CELL LUNG CANCER PATIENTS
This study looks at how long immunotherapy works for people with advanced lung cancer and how it affects their bodies. We're testing different drug combinations to see which works best and for how long, to improve treatment plans.
For: Patients with locally advanced or metastasic Non-Small Cell Lung Carcinoma.France - Ongoing, recruitingTherapeutic exploratory (Phase II)
PRODIGE 55-SOCRATE : A randomized phase II study to evaluate second-line ramucirumab alone or with paclitaxel in older patients with advanced gastric cancer
This study is looking at new ways to treat advanced stomach cancer in older patients. It compares two treatments, ramucirumab alone or with paclitaxel, to see which helps people live longer and have a better quality of life.
For: stomach cancer stage IV with metastasesFrance - Ongoing, recruitingPhase I and Phase II (Integrated)- Other
A5481092: PHASE 1/2 STUDY TO EVALUATE PALBOCICLIB (IBRANCE®) IN COMBINATION WITH IRINOTECAN AND TEMOZOLOMIDE OR IN COMBINATION WITH TOPOTECAN AND CYCLOPHOSPHAMIDE IN PEDIATRIC PATIENTS WITH RECURRENT OR REFRACTORY SOLID TUMORS
This study looks at new drug combinations for children with specific types of cancer (Ewing sarcoma or neuroblastoma) that have come back or not responded to previous treatment. It tests how safe and effective these combinations are.
For: recurrent/refractory Ewing sarcoma · recurrent or refractory neuroblastomaSweden · France · Czechia - Ongoing, recruitingTherapeutic exploratory (Phase II)
Perioperative Treatment in Resectable Gastric Cancer with Spartalizumab (PDR001) in Combination with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT): A phase II study (GASPAR)
This study is testing a new combination of treatments for stomach cancer that can be removed with surgery. It combines a new drug, spartalizumab, with a standard chemotherapy (FLOT). Researchers want to see if this new combination helps shrink the cancer more before surgery and improves outcomes.
For: Resectable Gastric CancerFrance - Ongoing, recruitingTherapeutic confirmatory (Phase III)
An open-label, randomised, multicentre, phase III study of irinotecan liposome injection, oxaliplatin, 5-fluorouracil/leucovorin versus nab-paclitaxel plus gemcitabine in subjects who have not previously received chemotherapy for metastatic adenocarcinoma of the pancreas
This study is testing a new combination of treatments for advanced pancreatic cancer that hasn't been treated with chemotherapy before. It compares a new drug mix (irinotecan liposome, oxaliplatin, 5-fluorouracil/leucovorin) against a standard treatment (nab-paclitaxel, gemcitabine) to see which helps people live longer.
For: Metastatic Pancreatic AdenocarcinomaSpain - Ongoing, recruitingTherapeutic exploratory (Phase II)
A multicentre phase II, open-label, non-randomized study evaluating Platinum-Pemetrexed-Atezolizumab ( Bevacizumab) for patients with stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutations, ALK rearrangement or ROS1 fusion progressing after Targeted therapies
This study looks at a new combination of existing medicines for a type of lung cancer (NSCLC) that has worsened after previous treatments. It aims to see how many patients respond positively to this new treatment approach.
For: Lung Cancer · NSCLCFrance - AuthorisedTherapeutic exploratory (Phase II)
A randomized non-comparative phase II study of Maintenance therapy with OSE2101 plus FOLFIRI, or FOLFIRI after induction therapy with FOLFIRINOX in patients with locally advanced or metastatic Pancreatic ductal adenocarcinoma.
This study looks at different treatment approaches for pancreatic cancer that has spread or is advanced. It combines standard chemotherapy with a new drug called OSE2101 or uses chemotherapy alone, after an initial treatment. The main goal is to see how long people live.
For: locally advanced or metastatic Pancreatic ductal adenocarcinomaFrance - Ongoing, recruitingTherapeutic exploratory (Phase II)
FFCD 1605- OPTIPRIME: A phase II study evaluating FOLFOX + panitumumab according to a ‘stop-and-go’ strategy with a reintroduction loop after progression on fluoropyrimidine as maintenance treatment, as the first line in patients with metastatic colorectal adenocarcinoma without a RAS mutation
This study is looking at a new way to treat bowel cancer that has spread. It combines existing medications, panitumumab and FOLFOX, using a 'stop-and-go' approach. The aim is to see how long the treatment keeps the cancer under control before it grows again, for patients without a specific gene change (RAS mutation).
For: metastatic colorectal adenocarcinomaFrance · Belgium - AuthorisedTherapeutic confirmatory (Phase III)
A randomized phase III trial of short-course versus long-course pre-operative chemotherapy with mFOLFIRINOX or PAXG regimen for stage I-III pancreatic ductal adenocarcinoma (PDAC)
This study looks at different ways to give chemotherapy before surgery for pancreatic cancer. We want to see if a shorter or longer course of treatment works better in helping people live longer and preventing the cancer from growing.
For: pancreatic ductal adenocarcinomaItaly - Ongoing, recruitingTherapeutic confirmatory (Phase III)
Pembrolizumab Alone versUs pembrolizumab-chemotherapy in first LInE NSCLC (PAULIEN)
This study is comparing two ways to treat advanced lung cancer (NSCLC) for the first time. We're looking at whether combining pembrolizumab with chemotherapy works better than pembrolizumab alone to shrink tumours or stop them from growing.
For: Advanced stage NSCLCNetherlands - Ongoing, recruitingTherapeutic exploratory (Phase II)
Open-label non-randomized multicentric phase 2 study evaluating the combination of bemarituzumab + FLOT chemotherapy in perioperative setting for resectable stage cT2-T4a or N+ gastric and GEJ adenocarcinoma overexpressing FGFR2b (BEMAFLOT)
This study looks at a new combination of a drug called bemarituzumab with standard chemotherapy for stomach and food pipe cancer. It checks how well this new treatment shrinks tumours before surgery in people with a specific type of cancer.
For: gastric and gastro-oesophageal junction adenocarcinomasFrance - AuthorisedPhase II and Phase III (Integrated)
A randomized, double-blinded, placebo-controlled, multicenter, phase II/III efficacy and safety study of oral TherO2-01S22 as add-on therapy on top of first line anti-HER2 targeted treatment of patients with Metastatic Breast Cancer TherO2-01S22 in HER2-positive breast cancer: TherO2-MBC Study
This study is testing a new drug, TherO2-01S22, for people with metastatic breast cancer that is HER2-positive. It aims to see how well it works and if it's safe when added to standard treatments. Researchers want to understand if it can shrink tumours.
For: metastatic breast cancerFrance - AuthorisedTherapeutic exploratory (Phase II)
PRODIGE 104 – NEOPREDICT A multicenter phase II trial using transcriptomic signatures to personalize neoadjuvant chemotherapy for patients with resectable borderline pancreatic adenocarcinoma.
This study looks at new ways to treat a specific type of pancreatic cancer that can be operated on. We're testing if personalising chemotherapy based on a patient's genes can improve treatment results and help people live longer and healthier lives.
For: Resectable borderline pancreatic adenocarcinomaFrance - AuthorisedTherapeutic confirmatory (Phase III)
Evaluation of the efficacy of iloprost in the management of vaso-occlusive crises in adult patients with sickle cell: a multicentre, randomised, double-blind, placebo-controlled study _ PROSTASICKLE
This study is testing if a drug called iloprost can help people with sickle cell anaemia during painful crises. It aims to see if iloprost can reduce the need for strong painkillers. This is a big study hoping to find a better way to manage these crises.
For: sickle cell anaemia with vaso-occlusive crisisFrance